152 related articles for article (PubMed ID: 8230734)
1. [In vitro susceptibility to fluconazole of fungal strains freshly isolated from child patients with deep-seated mycoses].
Yamaguchi H; Uchida K
Jpn J Antibiot; 1993 Aug; 46(8):647-53. PubMed ID: 8230734
[TBL] [Abstract][Full Text] [Related]
2. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
Pfaller MA; Castanheira M; Messer SA; Jones RN
Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
[TBL] [Abstract][Full Text] [Related]
3. [The in vitro antifungal activities of fluconazole against pathogenic yeasts recently isolated from clinical specimens].
Yamaguchi H; Igari J; Kume H; Abe M; Oguri T; Kanno H; Kawakami S; Okuzumi K; Fukayama M; Ito A; Kawata K; Uchida K
Jpn J Antibiot; 1997 Sep; 50(9):799-805. PubMed ID: 9394240
[TBL] [Abstract][Full Text] [Related]
4. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
5. [In vitro activity of a new semisynthetic echinocandin, micafungin, against clinical isolates of Candida species isolated in Tenri Hospital].
Komatsu M; Aihara M; Shimakawa K; Iwasaki M; Nagasaka Y; Fukuda S; Abe N; Matsuo S
Jpn J Antibiot; 2003 Dec; 56(6):705-11. PubMed ID: 15007879
[TBL] [Abstract][Full Text] [Related]
6. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method.
Pfaller MA; Barry AL
Mycopathologia; 1995; 130(1):3-9. PubMed ID: 7666925
[TBL] [Abstract][Full Text] [Related]
9. [In vitro antifungal activity of itraconazole, a new triazole antifungal agent, against clinical isolates from patients with systemic mycoses].
Uchida K; Matsuzaka A; Aoki K; Yamaguchi H
Jpn J Antibiot; 1991 May; 44(5):562-70. PubMed ID: 1652654
[TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts.
Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K
Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406
[TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole.
Morace G; Manzara S; Dettori G
Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
14. [Studies on microtiter broth dilution method for antifungal susceptibility testing of yeast isolates from blood and cerebrospinal fluid].
Fujita S
Rinsho Byori; 1996 Apr; 44(4):373-8. PubMed ID: 8847821
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of amphotericin B, flucytosine and fluconazole against yeasts causing bloodstream infections.
Berenguer J; Fernández-Baca V; Sánchez R; Bouza E
Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):362-5. PubMed ID: 7649205
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period.
Kucukates E; Erturan Z; Susever S; Yegenoglu Y
APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609
[TBL] [Abstract][Full Text] [Related]
17. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis.
Yang YL; Ho YA; Cheng HH; Ho M; Lo HJ
Infect Control Hosp Epidemiol; 2004 Jan; 25(1):60-4. PubMed ID: 14756222
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility testing of Candida isolates from clinical specimens to four antifungal agents.
Ohkawa M; Tokunaga S; Takashima M; Nishikawa T; Hisazumi H; Fujita S; Wheat RW
Chemotherapy; 1990; 36(6):396-402. PubMed ID: 2292203
[TBL] [Abstract][Full Text] [Related]
19. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of Candida species isolated from cancer patients to some antifungal agents.
Ozçelik B; Citak S; Cesur S; Abbasoğlu U; Içli F
Drug Metabol Drug Interact; 2004; 20(1-2):101-8. PubMed ID: 15283306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
